{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:12:01Z","timestamp":1695107521115},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>We present the case of a 2-month-old infant presenting with pallor and laboratory results showing: hemoglobin 5.1 (10 to 1.5)\u2009g\/dL, MCV 94.7 (75 to 105)\u2009fL, leukocytes 17.4 (7 to 15)\u2009\u00d710<jats:sup>3<\/jats:sup>\/\u03bcL, platelets 259 (150 to 450)\u2009\u00d710<jats:sup>3<\/jats:sup>\/\u03bcL, hyperbilirubinemia and renal dysfunction. A hemolytic anemia with tubular injury secondary to hemoglobinuria was suspected. Hyperhydration and packed cells were given but she deteriorated. Fluid overload with anuria further complicated the course necessating hemodialysis. Atypical hemolytic uremic syndrome was suspected and eculizumab was administered resulting in rapid improvement. Genetic analysis revealed a mutation in the gene encoding complement factor H and atypical hemolytic uremic syndrome was confirmed.<\/jats:p>","DOI":"10.1097\/mph.0000000000001209","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T21:57:04Z","timestamp":1525989424000},"page":"e111-e113","source":"Crossref","is-referenced-by-count":0,"title":["An Atypical Case of Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1097","volume":"41","author":[{"given":"Tine","family":"Francois","sequence":"first","affiliation":[{"name":"Pediatric Intensive Care"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Vande Walle","sequence":"additional","affiliation":[{"name":"Pediatrics, Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Dhont","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Keenswijk","sequence":"additional","affiliation":[{"name":"Pediatrics, Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium"},{"name":"Department of Pediatrics, Diakonessenhuis, Paramaribo, Suriname"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5935\/0101-2800.20140032","article-title":"Hemolytic-uremic syndrome in childhood","volume":"36","author":"Vaisbich","year":"2014","journal-title":"J Brasileiro Nefrol"},{"issue":"suppl 17","key":"R3-20230918","first-page":"1","article-title":"Atypical hemolytic uremic syndrome (aHUS): making the diagnosis","volume":"10","author":"Laurence","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/1744-9987.12609","article-title":"Atypical hemolytic uremic syndrome in low resource settings: which options do we have?","volume":"22","author":"Keenswijk","year":"2018","journal-title":"Ther Apher Dial"},{"key":"R7-20230918","first-page":"840","article-title":"Assessment of plasmapheresis report of the therapeutics and technology assessment","volume":"47","year":"1996","journal-title":"Neurology"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:46:02Z","timestamp":1695012362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001209","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}